Aditx Therapeutics Inc Stock

$1.33

14.74% yesterday

Nasdaq, Jun 27, 10:17 pm CET

ISIN

US0070251097

Symbol

ADTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Aditx Therapeutics Inc Stock price

$1.33

-101,199,998.67 100.00% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.23 14.74%

ISIN

US0070251097

Symbol

ADTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$3.2m

Enterprise Value

$5.9m

Net debt

$2.6m

Cash

$480.0k

Shares outstanding

1.2m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

53.89 | 0.15

EV/Sales

97.72 | 0.28

EV/FCF

negative

P/B

0.10

Financial Health

Equity Ratio

27.59%

Return on Equity

-454.96%

ROCE

-136.76%

ROIC

Debt/Equity

0.19

Financials (TTM | estimate)

Revenue

$60.0k | $21.3m

EBITDA

$-21.4m | -

EBIT

$-21.9m

Net Income

$-31.3m | $-306.1m

Free Cash Flow

$-22.5m

Growth (TTM | estimate)

Revenue

-88.24% | 16,255.38%

EBITDA

31.60% | -

EBIT

31.04%

Net Income

24.40% | -658.56%

Free Cash Flow

-9.32%

Margin (TTM | estimate)

Gross

-917.00%

EBITDA

-38,686.08% | -

EBIT

-39,667.63%

Net

-56,662.03% | -1,439.57%

Free Cash Flow

-40,713.56%

EPS

$-44.52

FCF per Share

$-18.61

Short interest

1.15%

Employees

26.00

Rev per Employee

$10.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Aditx Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Aditx Therapeutics Inc forecast:

6x Buy

75%

2x Hold

25%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Aditx Therapeutics Inc forecast:

Buy

75%

Hold

25%

Analyst Estimates with Stock Price Targets

Financial data from Aditx Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	0.06 0.06	88% 88% 100%
- Direct Costs	0.56 0.56	14% 14% 933%
Gross Profit	-0.51 -0.51	292% 292% -850%
- Selling and Administrative Expenses	17 17	2% 2% 29,133%
- Research and Development Expense	3.95 3.95	71% 71% 6,583%
EBITDA	-21 -21	32% 32% -35,650%
- Depreciation and Amortization	0.54 0.54	2% 2% 900%
EBIT (Operating Income) EBIT	-22 -22	31% 31% -36,560%
Net Profit	-31 -31	24% 24% -52,217%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aditx Therapeutics Inc Stock News

Neutral

Business Wire

●

2 days ago

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be presenting at Wall Street Reporter's NEXT SUPER STOCK livestream event on June 26, 2025 at 1:00 p.m. ET. Mr. Albanna will discuss Aditxt's innovation accelerati...

Neutral

PRNewsWire

●

17 days ago

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

-- BV Market Projected to Reach $1.0 Billion in the U.S. by 2033 -- -- BV Affects 21 Million U.S. Women; As many as 50% Experience Recurrent BV Within Six Months of Treatment -- SAN DIEGO , June 11, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) today announced that a study of SOLOSEC® (secnidazole) 2 g oral granules for recurrent bacterial vaginosis (BV) p...

Neutral

Business Wire

●

19 days ago

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) (“Evofem”), to Aditxt's Board of Directors. “We believe that Saundra's background as a CEO and entrepreneur, coupled with her de...

More Aditx Therapeutics Inc News

Company Profile

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Head office	United States
CEO	Amro Albanna
Employees	26
Founded	2017
Website	aditxt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now